The 2021 ESC/EACTS guidelines recommend all* sAS patients with severe aortic stenosis are referred to the Heart Team1

The new 2021 ESC/EACTS VHD guidelines recommend that all* symptomatic patients with severe aortic stenosis (sAS) are referred to the Heart Team for a treatment evaluation. The Heart Team will assess multiple patient factors, including their age, their values and preferences, when making the final decision between TAVI and SAVR.1

*With treatment indication.1

The Heart Team referral is the first step towards an optimal treatment decision

It is important that your patients with severe aortic stenosis (sAS) are provided the most appropriate treatment. The 2021 ESC/EACTS VHD guidelines recommend that the Heart Team evaluate treatment options using an individualised approach for every patient. Underpinning this, is the vital collateral information provided by their referring Cardiologist.1

Putting patients at the centre of the treatment decision

  • The 2021 ESC/EACTS VHD guidelines have emphasised the importance to incorporate patients’ values and preferences in the decision between TAVI or SAVR.1
  • A systematic review conducted in 2016 of patient values and preferences on aortic valve replacement therapy2 found great variability.2
  • The 2021 guidelines have taken the need to tailor care into account by advising that the Heart Team recommendation is discussed with each individual patient to allow them to make a fully informed decision.1

Our infographic outlines the new referral process and evaluation considerations that could now influence your final treatment decision1

Download the guidelines infographic

Articles similar to this

2021 ESC/EACTS Treatment Guidelines

Explore the latest updates in aortic stenosis management and see the impact this may have on your referral decisions.

Diagnosing Aortic Stenosis patients

It can be challenging confirming the AS severity and finding the optimal time to refer for further treatment.

Check our latest articles

View all articles

Stay informed with our newsletter

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.Read more


1  VahanianA,etal.EurHeartJ.2021;00:1-72
2 LytvynL,etal.BMJOpen.2016;6:e014327

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult where applicable).

PP--EU-3761 v2.0